After the Federal Circuit’s denial last month of Regeneron’s motion for an injunction pending appeal, seeking to prevent Amgen from ...
Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for ...
Study points to approach to improving anti-VEGF therapy for all wet AMD patients, and help subset of patients who lose vision ...
Dr Garg highlights new data showing that high-dose aflibercept could effectively extend treatment intervals, reducing the burden on patients, particularly working-age adults with busy schedules. Of ...
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a ...
A study from researchers at Wilmer Eye Institute, Johns Hopkins Medicine explains not only why some patients with wet ...
Regulatory Admission/IPOFormycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange 04.11.2024 / 06:30 CET/CESTThe issuer is solely responsible for the content of this ...
Detailed price information for Eyepoint Pharmaceuticals Inc (EYPT-Q) from The Globe and Mail including charting and trades.
Investigators presented numerous studies into new and developing therapies for diabetic macular edema and age-related macular degeneration that were aimed at reducing the treatment burden.
A preview of the next edition of BioWorld, ...
It is well-established that the availability of a prior art reference is dependent on the “effective filing date” of a patent or patent ...
Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback